|Bid||0.00 x 1200|
|Ask||0.00 x 900|
|Day's Range||221.72 - 223.89|
|52 Week Range||178.75 - 228.90|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||1.08|
|Expense Ratio (net)||0.43%|
Analysts Are Optimistic ahead of Boston Scientific's Q4 ResultsAnalysts’ recommendations and target priceBoston Scientific (BSX) is scheduled to post its fourth-quarter and 2018 earnings results on February 6, 2019. In this article, we’ll
Healthcare ETFs weakened Wednesday after Abbot Laboratories (ABT) slipped on a revenue miss and revealed an uninspiring forecast for the first quarter of the new year. The Health Care Select Sector SPDR ETF (XLV) fell 0.3% on Wednesday while the S&P 500 was 0.1% lower. Abbot Laboratories' quarterly revenue fell short of expectations due to lower sales of generic drugs in the emerging markets, Reuters reports.
The health care sector spent much of 2018 as the strongest performer across the market. For investors looking to take part in the health care sector, one of the easiest and most popular options is an exchange-traded fund (ETF). Given the popularity of the health care sector ETF space and the relative success of this corner of the financial world, there were several health care ETFs which were among the top performing ETFs overall for 2018.
On January 8, TransEnterix (TRXC) rose 11.15% compared to its previous closing price and reached $2.99 in its pre-market trading session. On January 7, TransEnterix issued a press release announcing its preliminary operational and financial performance for the fourth quarter and fiscal 2018. Based on the closing price on January 7, TransEnterix reported returns of 9.80% in the last week, -13.50% in the last month, and -53.70% in the last quarter.
While there have been losers in most corner of the space, several ETFs still managed to end the year in green and are likely to continue outperforming in 2019 too.
What market sell-off? These three sector ETFs wrapped up 2018 with double-digit gains even though Wall Street stumbled in October and fell hard.
Beaumont Capital Management aims to make investors comfortable by helping capture upside gains and protect against steep potential losses.
Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018. Medtronic’s net income in the first half of fiscal 2019 totaled $2.2 billion compared to $3.0 billion in the same period the prior year. Wall Street analysts anticipate that Medtronic is expected to report net income of $1.25 billion in the third quarter of fiscal 2019.
Medtronic’s Restorative Therapies Group consists of Spine, Brain, Specialty, and Pain therapies. Medtronic’s Restorative Therapies Group generated revenues of $2.0 billion in the second quarter of fiscal 2019 compared to $1.9 billion in the second quarter of fiscal 2018, reflecting ~7% YoY growth.
Markets have often rallied in the months after midterm elections (see chart below), but we are focused on what the new government makeup could mean for these sectors," Christopher Dhanraj, Director and Head of iShares Investment Strategy, said in a research note. Specifically, Dhanraj highlighted three U.S. segments to closely watch ahead. Something like the iShares U.S. Aerospace & Defense ETF (ITA) can be a pure play for those seeking exposure to the defense sector.
On November 26, Abiomed (ABMD) stock closed at $311.15, a ~3.92% rise from its previous day’s close of $299.41 on November 23. Abiomed stock rose from $187.41 at the close of market on December 29, 2017, to $311.15 at the close of market on November 26, 2018, reflecting a ~66% year-to-date rise.
Boston Scientific (BSX) stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23, 2018, reflecting a rise of ~40% year-to-date. On November 23, Boston Scientific stock closed at $34.80, a ~42% rise from its 52-week low of $24.54 on December 6, 2017.
Intuitive Surgical’s (ISRG) stock price rose from $364.94 at the close of market on December 29, 2017, to $489.57 on November 23, 2018, reflecting a ~34% year-to-date rise.
As part of its major restructuring plan, General Electric (GE) intends to spin off its Healthcare segment and turn it into a standalone entity. The company has planned the spin-off in a manner that maximizes shareholder wealth.
Even as the Democrats retook control of the House of Representatives and the Republicans maintained majority in the Senate, healthcare ETFs were also big winners following the 2018 Midterm Election results. ...
Count the iShares US Medical Devices ETF (NYSEArca: IHI) and the iShares US Healthcare ETF (NYSEArca: IYH) among the healthcare exchange traded funds that could be affected by the results of the upcoming ...
Thermo Fisher Scientific (TMO) reported its third quarter of 2018 results today, October 24. It surpassed Wall Street analysts’ estimates for both EPS and revenue. Its non-GAAP EPS was $2.62, and its revenues were $5.92 billion. That compares to analysts’ EPS estimate of $2.55 on revenues of $5.7 billion.
As we discussed in the previous part, Wall Street analysts expect Thermo Fisher Scientific (TMO) to report 11.5% revenue growth to $5.70 billion during the third quarter. Thermo Fisher provides products and services through its brands including Thermo Scientific, Fisher Scientific, Invitrogen, Unity Lab Services, and Applied Biosystems.
Zimmer Biomet Holdings (ZBH) plans to release its third-quarter earnings on October 26. Wall Street analysts expect ZBH to generate revenues of $1.8 billion in the third quarter.
In September 2018, Medtronic (MDT) announced that the company would acquire all outstanding shares of Mazor Robotics (MZOR) for $58.50 per American depositary share (or $29.25 per ordinary share), which amounts to a total of $1.64 billion (or $1.34 billion). Both companies’ boards of directors unanimously approved the transaction.
The Department of Justice issued a preliminary approval for CVS Pharmacy to acquire health care insurance company Aetna, possibly paving the way for transformative changes in the industry as cries for more affordable care emanating from consumers and regulators get louder. The Health Care Select Sector SPDR ETF (XLV) slid 0.42% as of 11:45 a.m. ET, Vanguard Health Care ETF (VHT) fell 0.54%, iShares US Medical Devices ETF (IHI) was down 1.21%, and iShares US Healthcare ETF (IYH) slid 0.55%. As part of the approval process, the DOJ set forth the condition that Aetna had to divest itself from its Medicare Part D drug plan, which it eventually sold to WellCare Health Plans for an undisclosed amount late last month.